You filled your Humira prescription the same way you have for years — and came home with something different. Or you got a letter saying your formulary is changing. Or your pharmacy called to say they can no longer fill Humira at your current copay.
This is happening to hundreds of thousands of patients in 2025 and 2026. Here's what's actually going on, what it means for your health, and what you can do about it.
Why Insurers Are Switching Patients
The three largest pharmacy benefit managers in the U.S. — CVS Caremark, Optum Rx, and Express Scripts — have been aggressively restructuring their adalimumab formularies over the past year. In many cases, they've removed brand Humira and some independent biosimilars from preferred tiers, while promoting their own "private-label" biosimilar products.
- CVS Caremark created Cordavis, a subsidiary that distributes Hyrimoz
- Optum Rx (UnitedHealth's PBM) created Nuvaila
- Express Scripts (Cigna's PBM) created Quallent
These arrangements give the PBMs better margins on the biosimilar products they're steering patients toward. For patients, the switch is often presented as a formulary change — which it is — but the business motivation is rarely explained.
Is It Safe to Be Switched?
For the large majority of patients: yes, with some important caveats.
FDA-approved adalimumab biosimilars have been through rigorous clinical trials demonstrating equivalent safety and efficacy to Humira. The underlying active ingredient is the same. Biosimilars that have received FDA interchangeable designation have cleared an even higher evidence bar.
The caveats:
Stable patients are different from newly starting patients. A patient who has been stable on Humira for years, with a well-established dosing schedule and no disease flares, faces different considerations than someone starting adalimumab treatment for the first time. The American College of Rheumatology and other specialty societies have specifically recommended against mandatory switching in stable patients.
The nocebo effect is real. Research shows that 1 in 8 patients who switch from Humira to a biosimilar return to Humira within 30 days — most without any demonstrable clinical reason. Knowing in advance that this is a psychological phenomenon (not a sign the drug isn't working) significantly reduces its occurrence.
Formulation matters. Make sure the biosimilar you're switched to uses a citrate-free formulation if injection-site pain has been a concern for you. Not all biosimilars match Humira's current formulation exactly.
Your Rights When Your Insurance Switches Your Drug
You are not required to accept a formulary-driven drug switch without recourse. Here are your options:
1. Request a medical exception (prior authorization appeal) If you and your doctor believe remaining on Humira is medically necessary — particularly if you've been stable for a long time and switching carries meaningful risk of disease flare — your prescriber can document this and file a medical exception request. Cite ACR guidance on non-mandatory switching for stable patients.
2. Ask for a 30-day transition fill Most states require insurers to provide at least a 30-day supply of a non-formulary drug at the formulary cost-sharing amount during a mid-year formulary change. Check your state's insurance rules.
3. File a grievance with your insurer If you were switched without adequate notice or in violation of your plan's terms, filing a formal grievance creates a paper trail and triggers a review process.
4. Contact your state insurance commissioner If your insurer's formulary change process didn't follow required notification rules, your state insurance commissioner is the appropriate escalation point.
If You Decide to Accept the Switch
If you and your doctor agree the biosimilar is appropriate, here's how to make the transition smoothly:
- Ask specifically for an interchangeable biosimilar (Cyltezo, Hadlima, Hyrimoz, or Yuflyma) — the FDA has cleared these for substitution without loss of efficacy
- Confirm it's the citrate-free formulation if that matters to you
- Keep your first few injections at the same schedule as Humira — don't change timing or dose during the transition
- Report any changes in symptoms to your prescriber promptly — but be aware that minor adjustment periods are normal
ClariMeds can help you understand the assistance programs available for any biosimilar you're transitioned to, so cost doesn't become an additional barrier during the switch.
This article is for informational purposes only. Always consult your prescribing physician before making any changes to your medication.